Spots Global Cancer Trial Database for Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
Official Title: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
Study ID: NCT06084299
Conditions
Interventions
Study Description
Brief Summary: Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.
Detailed Description: This is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process for the treatment of patients with advanced liver cancer. The cell transfer therapy used in this study involves patients receiving a non-myeloablative lymphodepletion preparative regimen, followed by i.v. infusion of autologous tumor-infiltrating lymphocytes followed by the administration of a regimen of IL-2.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tongji Hospital, Wuhan, , China
Contact Details
Name: Zhiyong Huang
Affiliation: Tongji Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
